Irotecan IV Infusion

Introduction

Irinotecan hydrochloride is a chemotherapy medication used primarily in the treatment of various cancers, including colorectal cancer. It is a topoisomerase I inhibitor that interferes with DNA replication in cancer cells, leading to cell death.

Uses

Irinotecan hydrochloride is used for:

Treating metastatic colorectal cancer, either as a single agent or in combination with other chemotherapy drugs.
Managing other cancers such as small cell lung cancer and certain types of ovarian cancer, as part of combination chemotherapy regimens.

It is often used when other treatments have failed or in specific cancer regimens recommended by oncologists.

Brand Name	Irotecan
Type	IV Infusion
Weight	20 mg/ml
Generic	Irinotecan Hydrochloride
Manufacturer	Healthcare Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Irinotecan hydrochloride works by inhibiting topoisomerase I, an enzyme crucial for DNA replication. This inhibition prevents the relaxation of supercoiled DNA, leading to DNA strand breaks and ultimately cell death. The drug exerts its effects during the S phase of the cell cycle.

How Long Does It Take to Work?

The onset of action for irinotecan hydrochloride can vary. Some patients may start to see effects within a few weeks of starting treatment, but significant clinical responses typically take several cycles of therapy. The duration to notice benefits depends on the cancer type and individual response to the drug.

Absorption

Irinotecan hydrochloride is administered intravenously, so it is directly absorbed into the bloodstream. There is no significant oral absorption as the drug is not available in oral form. The intravenous route ensures immediate availability for its therapeutic effects.

Route of Elimination

The drug is primarily metabolized in the liver by carboxylesterases to its active metabolite, SN-38. Both irinotecan and SN-38 are then excreted via the bile into the feces, with a small amount excreted in the urine.

Dosage

Colorectal cancer combination regimen 1: Irinotecan 125 mg/m² intravenous infusion over 90 minutes on days 1, 8,15, 22 with LV 20 mg/m² intravenous bolus infusion on days 1, 8, 15, 22 followed by 5-FU intravenous bolus infusion on days 1, 8, 15, 22 every 6 weeks.

Colorectal cancer combination regimen 2: Irinotecan 180 mg/m2 intravenous infusion over 90 minutes on days 1, 15, 29 with LV 200 mg/m² intravenous infusion over 2 hours on days 1, 2, 15, 16, 29, 30 followed by 5-FU 400 mg/m 2 intravenous bolus infusion on days 1, 2, 15, 16, 29, 30 and 5-FU 600 mg/m 2 intravenous infusion over 22 hours on days 1, 2, 15, 16, 29, 30.

Colorectal cancer single agent regimen 1: Irinotecan 125 mg/m² intravenous infusion over 90 minutes on days 1, 8, 15, 22 then 2-week rest.

Colorectal cancer single agent regimen 2: Irinotecan 350 mg/m² intravenous infusion over 90 minutes on day 1 every 3 weeks.

The dosage of irinotecan hydrochloride varies based on the type of cancer and treatment regimen:

For colorectal cancer: Typically 180-300 mg/m² every 2 weeks, administered via intravenous infusion.
In combination regimens: Dosages may vary and are adjusted according to the specific combination and schedule.

Dosage adjustments may be needed based on tolerability, side effects, and patient-specific factors.

Administration

Irinotecan hydrochloride is administered intravenously over a period of 30 to 90 minutes, depending on the treatment regimen. It is important to follow the prescribed infusion rates and schedules to minimize side effects and maximize efficacy.

Side Effects

Common side effects include:

Diarrhea, which can be severe and requires prompt management.
Nausea and vomiting.
Fatigue and weakness.
Neutropenia (low white blood cell count), increasing the risk of infection.

Serious side effects may include severe gastrointestinal symptoms, infections, and liver toxicity. Regular monitoring is required to manage these effects effectively.

Toxicity

Toxicity of irinotecan hydrochloride can manifest as:

Severe diarrhea, which can lead to dehydration and electrolyte imbalances.
Neutropenia and anemia, which can increase the risk of infections and other complications.
Hepatotoxicity, with possible liver enzyme abnormalities.

Dose adjustments or supportive treatments may be needed to address toxicity and maintain safety.

Precautions

Precautions include:

Monitoring for and managing severe diarrhea promptly to avoid dehydration.
Regular blood tests to check for neutropenia and liver function abnormalities.
Use with caution in patients with hepatic impairment or a history of gastrointestinal issues.

Adjustments to dosage and supportive care are often required based on individual patient responses.

Interaction

Irinotecan hydrochloride may interact with other medications, including:

Drugs affecting liver enzymes, such as CYP3A4 inhibitors or inducers, which can alter irinotecan metabolism.
Medications affecting gastrointestinal motility, which can impact the severity of diarrhea.

Inform your healthcare provider of all medications and supplements to manage potential interactions.

Disease Interaction

Use with caution in patients with:

Liver disease or hepatic impairment, as irinotecan is metabolized in the liver.
Active gastrointestinal disease, which can exacerbate side effects like diarrhea.

Regular monitoring and adjustments are necessary to manage these conditions effectively during treatment.

Drug Interaction

Drug interactions may include:

CYP3A4 inhibitors (e.g., ketoconazole) may increase irinotecan levels, potentially enhancing side effects.
CYP3A4 inducers (e.g., rifampin) may reduce irinotecan efficacy by increasing its metabolism.

Adjustments to dosages or alternative therapies may be required based on drug interactions.

Food Interactions

There are no specific food interactions with irinotecan hydrochloride. However, managing gastrointestinal side effects such as nausea and diarrhea may require dietary adjustments as advised by a healthcare provider.

Pregnancy Use

Irinotecan hydrochloride is generally contraindicated during pregnancy due to potential harm to the fetus. If pregnancy occurs during treatment, consult a healthcare provider for guidance and possible alternative treatments.

Lactation Use

Due to the potential for serious adverse effects on the nursing infant, irinotecan hydrochloride is usually not recommended during lactation. Alternatives should be considered, and breastfeeding should be discontinued if treatment is necessary.

Acute Overdose

Acute overdose symptoms may include:

Severe gastrointestinal symptoms such as prolonged diarrhea and dehydration.
Increased risk of severe neutropenia and infection.

Seek immediate medical attention in case of overdose. Supportive care and dose adjustments may be required.

Contraindication

Contraindications include:

Hypersensitivity to irinotecan or any of its components.
Severe hepatic impairment or active liver disease.
Severe diarrhea or gastrointestinal obstruction.

Avoid use in these conditions and consult a healthcare provider for alternative treatment options.

Use Direction

Follow the specific dosing and administration instructions provided by your healthcare provider. Regular monitoring and adherence to the prescribed regimen are crucial for the effectiveness and safety of the treatment.

Storage Conditions

Store irinotecan hydrochloride at room temperature, away from light and moisture. Ensure the medication is kept out of reach of children and used only as directed.

Volume of Distribution

The volume of distribution of irinotecan hydrochloride is approximately 1.5 L/kg, indicating its distribution throughout the body tissues.

Half Life

The half-life of irinotecan hydrochloride is approximately 6 to 12 hours. The active metabolite, SN-38, has a longer half-life of about 15 to 20 hours, which influences the drug's therapeutic effects.

Clearance

The clearance of irinotecan hydrochloride is primarily hepatic, with the liver playing a key role in its metabolism and elimination. Renal clearance also contributes to the overall elimination process.

See in details version Irotecan IV Infusion 20 mg/ml also Irotecan IV Infusion 20 mg/ml in bangla